Vaxxinova possesses multiple innovative aquatic vaccine products and immersion vaccination technologies that lead the industry. We are actively seeking collaboration partners worldwide through single or multiple product external authorization models. This approach aims to maximize product value while accelerating global market development and commercialization. Our goal is to provide safer and more efficient disease prevention and control solutions for the global aquaculture industry.

Wankesen's self-developed nanomaterial carrier - the antigen complex technology platform and the immersion-type vaccine delivery technology platform possess the capability to break through the limitations of traditional vaccine methods. They have gained recognition from multiple key domestic scientific research institutions and aquaculture enterprises. We welcome cooperative partners with specific needs to utilize Wankesen's proprietary technology platforms to develop innovative aquatic vaccine products that meet market demands.

Vankoson possesses comprehensive R&D capabilities spanning from product discovery to clinical application. We are committed to collaborating closely with our partners, integrating the superior resources and technologies of both parties. Through joint research, co-development, and commercial promotion, we aim to explore multiple avenues to collectively address the challenges posed by diseases in the aquaculture industry.

Wankesen maintains an open attitude towards introducing innovative technologies that can address pain points in the prevention and control of diseases in the aquaculture industry. This approach aims to expand our product portfolio in the field of aquatic animal health. Simultaneously, we also seek to license cutting-edge technologies that complement our own platform, further enhancing our research and development capabilities in the area of innovative aquatic vaccines.

While focusing on building its own capabilities and product development, Vankeshen maintains an open attitude toward other forms of cooperation. For example, it establishes joint ventures with investment funds or other companies to collaboratively research, develop, and commercialize specific products. It also engages in early-stage research collaborations with institutions such as research academies, universities, and startups. Leveraging our new materials technology platform and clinical application experience, we assist our partners in rapidly advancing their innovative disease prevention and control technologies with market potential into the application phase.